Moreover, AFAP1L2-SRC-FUNDC1 pathway-dependent mitophagy has been demonstrated to be involved in mitigating sorafenib resistance in hepatocellular carcinoma cells47. Here, FUNDC1 is linked to hepatocellular carcinoma.